2nd Quarter - Report

NVG, LLC for ALEXION PHARMACEUTICALS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2018 $50,000 Replaced
2nd Quarter - Amendment Oct 10, 2018 $60,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues; H.R. 1231/S. 456 - Research to Accelerate Cures and Equity for Children Act.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
PATRICIA GRIFFIN —
ANDREA LARUE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1231 (115th), S. 456 (115th)

Copyright/Patent/Trademark CPT

Intellectual property and potential changes to the patent system, generally

LobbyistCovered position, as disclosed
ANDREA LARUE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Orphan drug payments under Medicare.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
ANDREA LARUE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.